The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Highlights from day 2: MRD in myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some highlights from the second day of COMy 2022, which focused on the role of measurable residual disease (MRD) in multiple myeloma. Prof. Mohty discusses some of the sessions and debates held throughout the day, which addressed the role of MRD from a prognostic point of view, as well as its role in guiding treatment. Prof. Mohty also mentions some of the trials discussed during these sessions, including the MASTER-2 trial (NCT05231629) and the MIDAS (NCT04934475) trial, and concludes by addressing the value of MRD in real-life practice. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
